Clinical features of and effects of angiotensin system antagonists on amiodarone-induced pulmonary toxicity

Akira Nikaido, Takeshi Tada, Kazufumi Nakamura, Masato Murakami, Kimikazu Banba, Nobuhiro Nishii, Soichiro Fuke, Satoshi Nagase, Satoru Sakuragi, Hiroshi Morita, Tohru Ohe, Kengo Fukushima Kusano

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Amiodarone (AMD) is a strong antiarrhythmic drug but has severe side effects such as pulmonary toxicity. There are no indicators or drugs that can prevent the development of amiodarone-induced pulmonary toxicity (AIPT). Methods: We collected data for 96 consecutive patients treated with AMD and analyzed clinical factors related to AIPT. In addition, we examined the effect of AMD and angiotensin II (Ang II) on human lung alveolar epithelial cells (AEC) and verified the protective efficacy of an Ang II type 1 receptor blocker (ARB) in vitro. Results: During a follow-up period of 33.8±34.6 months, AIPT developed in 11 patients (11.5%). There were no differences in the dose of AMD, left ventricular ejection fraction, serum KL-6 and %DLCO level before starting AMD between patients with and those without AIPT. However, repeated episodes of congestive heart failure (CHF) were observed more frequently in patients with AIPT than in patients without AIPT (81.8% vs. 41.2%, P

Original languageEnglish
Pages (from-to)328-335
Number of pages8
JournalInternational Journal of Cardiology
Volume140
Issue number3
DOIs
Publication statusPublished - Apr 30 2010

Fingerprint

Amiodarone
Angiotensins
Lung
Alveolar Epithelial Cells
Angiotensin II Type 1 Receptor Blockers
Anti-Arrhythmia Agents
Angiotensin II
Stroke Volume
Heart Failure

Keywords

  • Amiodarone
  • Angiotensin
  • Antiarrhythmia agents
  • Apoptosis
  • Heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Clinical features of and effects of angiotensin system antagonists on amiodarone-induced pulmonary toxicity. / Nikaido, Akira; Tada, Takeshi; Nakamura, Kazufumi; Murakami, Masato; Banba, Kimikazu; Nishii, Nobuhiro; Fuke, Soichiro; Nagase, Satoshi; Sakuragi, Satoru; Morita, Hiroshi; Ohe, Tohru; Kusano, Kengo Fukushima.

In: International Journal of Cardiology, Vol. 140, No. 3, 30.04.2010, p. 328-335.

Research output: Contribution to journalArticle

Nikaido, Akira ; Tada, Takeshi ; Nakamura, Kazufumi ; Murakami, Masato ; Banba, Kimikazu ; Nishii, Nobuhiro ; Fuke, Soichiro ; Nagase, Satoshi ; Sakuragi, Satoru ; Morita, Hiroshi ; Ohe, Tohru ; Kusano, Kengo Fukushima. / Clinical features of and effects of angiotensin system antagonists on amiodarone-induced pulmonary toxicity. In: International Journal of Cardiology. 2010 ; Vol. 140, No. 3. pp. 328-335.
@article{95c51f8e35f040c685fdf1cddd9f07e4,
title = "Clinical features of and effects of angiotensin system antagonists on amiodarone-induced pulmonary toxicity",
abstract = "Background: Amiodarone (AMD) is a strong antiarrhythmic drug but has severe side effects such as pulmonary toxicity. There are no indicators or drugs that can prevent the development of amiodarone-induced pulmonary toxicity (AIPT). Methods: We collected data for 96 consecutive patients treated with AMD and analyzed clinical factors related to AIPT. In addition, we examined the effect of AMD and angiotensin II (Ang II) on human lung alveolar epithelial cells (AEC) and verified the protective efficacy of an Ang II type 1 receptor blocker (ARB) in vitro. Results: During a follow-up period of 33.8±34.6 months, AIPT developed in 11 patients (11.5{\%}). There were no differences in the dose of AMD, left ventricular ejection fraction, serum KL-6 and {\%}DLCO level before starting AMD between patients with and those without AIPT. However, repeated episodes of congestive heart failure (CHF) were observed more frequently in patients with AIPT than in patients without AIPT (81.8{\%} vs. 41.2{\%}, P",
keywords = "Amiodarone, Angiotensin, Antiarrhythmia agents, Apoptosis, Heart failure",
author = "Akira Nikaido and Takeshi Tada and Kazufumi Nakamura and Masato Murakami and Kimikazu Banba and Nobuhiro Nishii and Soichiro Fuke and Satoshi Nagase and Satoru Sakuragi and Hiroshi Morita and Tohru Ohe and Kusano, {Kengo Fukushima}",
year = "2010",
month = "4",
day = "30",
doi = "10.1016/j.ijcard.2008.11.106",
language = "English",
volume = "140",
pages = "328--335",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Clinical features of and effects of angiotensin system antagonists on amiodarone-induced pulmonary toxicity

AU - Nikaido, Akira

AU - Tada, Takeshi

AU - Nakamura, Kazufumi

AU - Murakami, Masato

AU - Banba, Kimikazu

AU - Nishii, Nobuhiro

AU - Fuke, Soichiro

AU - Nagase, Satoshi

AU - Sakuragi, Satoru

AU - Morita, Hiroshi

AU - Ohe, Tohru

AU - Kusano, Kengo Fukushima

PY - 2010/4/30

Y1 - 2010/4/30

N2 - Background: Amiodarone (AMD) is a strong antiarrhythmic drug but has severe side effects such as pulmonary toxicity. There are no indicators or drugs that can prevent the development of amiodarone-induced pulmonary toxicity (AIPT). Methods: We collected data for 96 consecutive patients treated with AMD and analyzed clinical factors related to AIPT. In addition, we examined the effect of AMD and angiotensin II (Ang II) on human lung alveolar epithelial cells (AEC) and verified the protective efficacy of an Ang II type 1 receptor blocker (ARB) in vitro. Results: During a follow-up period of 33.8±34.6 months, AIPT developed in 11 patients (11.5%). There were no differences in the dose of AMD, left ventricular ejection fraction, serum KL-6 and %DLCO level before starting AMD between patients with and those without AIPT. However, repeated episodes of congestive heart failure (CHF) were observed more frequently in patients with AIPT than in patients without AIPT (81.8% vs. 41.2%, P

AB - Background: Amiodarone (AMD) is a strong antiarrhythmic drug but has severe side effects such as pulmonary toxicity. There are no indicators or drugs that can prevent the development of amiodarone-induced pulmonary toxicity (AIPT). Methods: We collected data for 96 consecutive patients treated with AMD and analyzed clinical factors related to AIPT. In addition, we examined the effect of AMD and angiotensin II (Ang II) on human lung alveolar epithelial cells (AEC) and verified the protective efficacy of an Ang II type 1 receptor blocker (ARB) in vitro. Results: During a follow-up period of 33.8±34.6 months, AIPT developed in 11 patients (11.5%). There were no differences in the dose of AMD, left ventricular ejection fraction, serum KL-6 and %DLCO level before starting AMD between patients with and those without AIPT. However, repeated episodes of congestive heart failure (CHF) were observed more frequently in patients with AIPT than in patients without AIPT (81.8% vs. 41.2%, P

KW - Amiodarone

KW - Angiotensin

KW - Antiarrhythmia agents

KW - Apoptosis

KW - Heart failure

UR - http://www.scopus.com/inward/record.url?scp=77953561520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953561520&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2008.11.106

DO - 10.1016/j.ijcard.2008.11.106

M3 - Article

VL - 140

SP - 328

EP - 335

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 3

ER -